LEO Pharma is a Danish multinational pharmaceutical company that operates under the LEO Foundation. The company specialises in medical dermatology and seeks to become a world leader in this area of medicine. LEO Pharma undertakes research and development (R&D) activity to aid in the discovery of new medicines and the refinement of existing ones.

The French division of LEO Pharma offers the Charles Grupper prizes to recognise excellent quality in recent articles published in dermatology by French researchers or clinicians aged 45 or under. The Prizes will recognise either basic or clinical research.

Three prizes will be awarded in two categories:

• Category 1: Two prizes will be awarded to young clinicians or researchers for an article accepted or published during the current or previous calendar year for which the applicant is first author. The article may involve basic or clinical research. For this category, eligible applicants are young dermatology clinicians or researchers (aged under 45). The article must have been published in 2024 or 2025.
• Category 2: One prize will be awarded to a dermatologist working on the research and/or implementation of a digital and/or technological device with applications for medical dermatology (diagnostics, decision-making, treatment monitoring or observation, prevention, coordination of care, patient quality of life support).

For both categories, research must have been completed either in France or in a francophone country. For the purpose of these prizes, francophone countries are defined as countries with medical schools that belong to a francophone conference of deans. Eligible research may have been completed by an individual or a team.

The amount awarded for each prize will be decided by LEO Pharma by 1 October 2025. Each prize will be worth no less than €5,000.